Robust Pipeline with Multiple T-Cell Immunotherapy Product Candidates in Clinical Development

tab-cel™(tabelecleucel)
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
RR EBV+PTLD following HCT(1)

RR EBV+PTLD following SOT

1st line EBV+PTLD

EAP:RR PTLD and other EBV+cancers(2)

Nasopharyngeal carcinoma(3)

MS Portfolio
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Autologous ATA190 Progressive MS

Allogeneic ATA188 Progressive MS and RRMS

ATA230
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Refractory CMV Infection and Disease Post HCT/SOT

Atara CAR T Pipeline
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
ATA2321

ATA2431

ATA3219

Other CAR T Program

Other CAR T Program

Other CAR T Program

Other Programs
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
ATA520:Hematologic malignancies

ATA621